Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Optimization and Application of the Endosomal Escape Vehicle (EEV™) Platform for Enhanced Delivery of Oligonucleotides to Skeletal and Cardiac Muscle
- By: Xiang Li, PhD, Director, Discovery Research, Entrada Therapeutics
- At: ASGCT 27TH Annual Meeting
- On: May 7, 2024
DownloadMay 7, 2024 -
Exon Skipping and Dystrophin Production with Endosomal Escape Vehicle (EEV™) - Oligonucleotide Conjugates in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President Neuromuscular, Entrada Therapeutics
- At: 8th International Myology Congress
- On: April 22, 2024
DownloadApril 22, 2024 -
Therapeutic Potential of Endosomal Escape Vehicle (EEV™)-Oligonucleotide Conjugates in Preclinical Models of Neuromuscular Diseases
- By: Mahasweta Girgenrath, PhD, Vice President Neuromuscular, Entrada Therapeutic
- At: 3rd Annual Solve FSHD Conference
- On: April 4, 2024
DownloadApril 4, 2024 -
Development and Optimization of the Endosomal Escape Vehicle (EEV™) Platform to Enhance the Intracellular Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: TIDES Asia 2024
- On: March 19, 2024
DownloadMarch 19, 2024 -
Development and Optimization of the Endosomal Escape Vehicle (EEV™) Platform to Enhance the Intracellular Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 9th Annual Oligonucleotide & Precision Therapeutics (OPT) Conference
- On: March 14, 2024
DownloadMarch 14, 2024 -
Exon Skipping and Dystrophin Production with Endosomal Escape Vehicle (EEV™) - Oligonucleotide Conjugates in Preclinical Models of DMD
- By: Mahasweta Girgenrath, PhD, Vice President Neuromuscular, Entrada Therapeutics
- At: 2024 MDA Clinical & Scientific Conference
- On: March 3, 2024
DownloadMarch 3, 2024